| Robert D Maclachlan, MD | |
|
4141 5th St, Rapid City, SD 57701-6021 | |
| (605) 341-2424 | |
| (605) 341-4547 |
| Full Name | Robert D Maclachlan |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 31 Years |
| Location | 4141 5th St, Rapid City, South Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265491195 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 4985 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Black Hills Surgical Hospital Llp | Rapid city, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Black Hills Orthopedic And Spine Center Of Wyoming Pc | 4789929357 | 14 |
| Black Hills Orthopedic And Spine Center Pc | 0648172932 | 65 |
News Archive
Accuray Incorporated, the premier radiation oncology company, announced today the launch of the Prostate Advances in Comparative Evidence (PACE) Study, an international, multi-center, randomized study to compare CyberKnife® Stereotactic Body Radiation Therapy (SBRT), da Vinci assisted and manual laparoscopic surgery and conventionally fractionated intensity modulated radiation therapy (IMRT), for the treatment of localized prostate cancer.
Immunologists Barbara A. Osborne and Lisa M. Minter at the University of Massachusetts Amherst, as part of a multi-institution research team, will share a five-year, $4.8 million National Cancer Institute grant to target multiple diseases including cancer, Alzheimer's and graft-versus-host disease (GVHD) by manipulating an enzyme that activates over 100 different protein substrates in the body.
Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence but shows no positive difference in terms of overall survival (OS) or distant brain metastases (DBMs) rates, when compared to observation alone following surgical resection of brain metastases, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.
Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.
› Verified 3 days ago
| Entity Name | Black Hills Orthopedic & Spine Center Of Wyoming Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538644679 PECOS PAC ID: 4789929357 Enrollment ID: O20181231001466 |
News Archive
Accuray Incorporated, the premier radiation oncology company, announced today the launch of the Prostate Advances in Comparative Evidence (PACE) Study, an international, multi-center, randomized study to compare CyberKnife® Stereotactic Body Radiation Therapy (SBRT), da Vinci assisted and manual laparoscopic surgery and conventionally fractionated intensity modulated radiation therapy (IMRT), for the treatment of localized prostate cancer.
Immunologists Barbara A. Osborne and Lisa M. Minter at the University of Massachusetts Amherst, as part of a multi-institution research team, will share a five-year, $4.8 million National Cancer Institute grant to target multiple diseases including cancer, Alzheimer's and graft-versus-host disease (GVHD) by manipulating an enzyme that activates over 100 different protein substrates in the body.
Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence but shows no positive difference in terms of overall survival (OS) or distant brain metastases (DBMs) rates, when compared to observation alone following surgical resection of brain metastases, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.
Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert D Maclachlan, MD Po Box 6850, Rapid City, SD 57709-6850 Ph: (605) 341-1414 | Robert D Maclachlan, MD 4141 5th St, Rapid City, SD 57701-6021 Ph: (605) 341-2424 |
News Archive
Accuray Incorporated, the premier radiation oncology company, announced today the launch of the Prostate Advances in Comparative Evidence (PACE) Study, an international, multi-center, randomized study to compare CyberKnife® Stereotactic Body Radiation Therapy (SBRT), da Vinci assisted and manual laparoscopic surgery and conventionally fractionated intensity modulated radiation therapy (IMRT), for the treatment of localized prostate cancer.
Immunologists Barbara A. Osborne and Lisa M. Minter at the University of Massachusetts Amherst, as part of a multi-institution research team, will share a five-year, $4.8 million National Cancer Institute grant to target multiple diseases including cancer, Alzheimer's and graft-versus-host disease (GVHD) by manipulating an enzyme that activates over 100 different protein substrates in the body.
Stereotactic radiosurgery (SRS) for cancer patients who receive the treatment for brain metastases decreases the likelihood of local recurrence but shows no positive difference in terms of overall survival (OS) or distant brain metastases (DBMs) rates, when compared to observation alone following surgical resection of brain metastases, according to research presented today at the 58th Annual Meeting of the American Society for Radiation Oncology.
Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.
› Verified 3 days ago
Steven K Hata, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2929 5th Street, 240, Rapid City, SD 57701 Phone: 605-341-3770 Fax: 605-341-8692 | |
Dr. Douglas Thorburn Brown, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2929 5th Street, 240, Rapid City, SD 57701 Phone: 605-341-3770 Fax: 605-341-8692 | |
Kirsten A Butz, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 915 Mt View Rd, Rapid City, SD 57702 Phone: 605-755-7300 Fax: 605-755-0707 | |
Dr. Terry R Hicks, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 350 Elk St, Rapid City, SD 57701 Phone: 605-343-7262 Fax: 605-343-7293 | |
Dr. Ryan Gianatasio, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 677 Cathedral Dr, Rapid City, SD 57701 Phone: 605-755-4150 | |
Dr. Mark Thomas Garry, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 10 Van Buren St, Rapid City, SD 57701 Phone: 605-721-8939 | |
Heather G Cwach, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2929 5th Street, 240, Rapid City, SD 57701 Phone: 605-341-3770 Fax: 605-341-8692 |